D. Beirne

TL;DR: It is shown, in a window-of-opportunity clinical study, that intravenous infusion of oncolytic human Orthoreovirus leads to infection of tumor cells subsequently resected as part of standard clinical care, both in high-grade glioma and in brain metastases, and increases cytotoxic T cell tumor infiltration relative to patients not treated with virus.

TL;DR: It is shown in human patients with colorectal cancer that, after intravenous injection, reovirus can be escorted to the tumor by immune cells, which protect it from neutralizing antibodies in the plasma, and potentially cloud-lifting studies support intravenous administration of reov virus for cancer therapy.

TL;DR: It is concluded that SRL172 may have activity in metastatic renal cancer and has very low toxicity, making it worthy of further study.

TL;DR: The combination of temozolomide and lomustine in patients with brain metastases from melanoma does not demonstrate activity and further evaluation of this combination is not warranted.

TL;DR: Preclinical data have shown that the combination of reovirus (REO) and radia ( radia) in combination with conventional chemotherapy results in down-regulation in mice with Ras-pathway signaling disorders.